OTLK - Outlook Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5
32.19M
Enterprise Value 3
38.9M
Trailing P/E
N/A
Forward P/E 1
-1.09
PEG Ratio (5 yr expected) 1
N/A
Price/Sales (ttm)
10.50
Price/Book (mrq)
N/A
Enterprise Value/Revenue 3
12.69
Enterprise Value/EBITDA 6
-1.31

Trading Information

Stock Price History

Beta (3Y Monthly) -0.76
52-Week Change 3-75.00%
S&P500 52-Week Change 318.93%
52 Week High 310.9600
52 Week Low 30.8500
50-Day Moving Average 31.1871
200-Day Moving Average 31.7325

Share Statistics

Avg Vol (3 month) 3378.96k
Avg Vol (10 day) 31.96M
Shares Outstanding 528.23M
Float 13.19M
% Held by Insiders 142.05%
% Held by Institutions 12.54%
Shares Short (Nov 15, 2019) 41.35M
Short Ratio (Nov 15, 2019) 49.07
Short % of Float (Nov 15, 2019) 410.21%
Short % of Shares Outstanding (Nov 15, 2019) 44.77%
Shares Short (prior month Oct 15, 2019) 4864.12k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 28/1
Last Split Date 3Mar 18, 2019

Financial Highlights

Fiscal Year

Fiscal Year Ends Sep 30, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)-1,077.53%

Management Effectiveness

Return on Assets (ttm)-61.33%
Return on Equity (ttm)N/A

Income Statement

Revenue (ttm)3.06M
Revenue Per Share (ttm)0.23
Quarterly Revenue Growth (yoy)-24.40%
Gross Profit (ttm)-15.42M
EBITDA -29.72M
Net Income Avi to Common (ttm)-38.43M
Diluted EPS (ttm)-2.8860
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)14.03M
Total Cash Per Share (mrq)0.5
Total Debt (mrq)14.98M
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)0.81
Book Value Per Share (mrq)-0.23

Cash Flow Statement

Operating Cash Flow (ttm)-34.77M
Levered Free Cash Flow (ttm)-26.32M